University of Arizona College of Medicine, Phoenix, AZ, USA.
Norton Thoracic Institute, 6586St Joseph's Hospital and Medical Center, Phoenix, AZ, USA.
Prog Transplant. 2020 Sep;30(3):235-242. doi: 10.1177/1526924820933830. Epub 2020 Jun 25.
Most lung transplant patients are older than 50 years. Complications from colonic diverticula are not uncommon, especially with chronic immunosuppression. However, limited data exist regarding the optimal management of these patients. We sought to investigate the incidence, risk factors, and outcomes of diverticulitis after lung transplant.
We conducted a retrospective study to review patients undergoing lung transplant between 2007 and 2016 with posttransplant acute colonic diverticulitis. Patients were grouped based on medical or surgical management.
Of 512 transplant recipients, 17 (3.32%) developed 26 episodes of diverticulitis over a median follow-up of 39 months. Nine patients had documented diverticulosis on pretransplant colonoscopy. These patients had a higher incidence of surgical intervention for diverticulitis, were more likely to have recurrent diverticulitis, and had longer lengths of stay than patients without pretransplant diverticulosis. Six (35.3%) of 17 patients required surgery (ie, Hartmann procedure; 4 during the initial episode and 2 during their third and fourth episodes); 11 patients (64.7%) were managed with antibiotics alone. Patients in the surgical group presented earlier posttransplant ( = .004) and were on higher doses of tacrolimus ( = .03). Six (46.1%) of 13 patients with medically managed first episodes of diverticulitis experienced recurrence. No recurrence occurred after surgical management. No deaths were attributable to diverticulitis in either group.
Patients with pretransplant diverticulosis experienced earlier, more complicated episodes of diverticulitis posttransplant than patients without. Surgical patients received higher doses of tacrolimus and presented earlier than medical patients. Uncomplicated diverticulitis in posttransplant patients can be managed medically, even in the case of recurrent, uncomplicated disease.
大多数肺移植患者年龄超过 50 岁。由于慢性免疫抑制,结肠憩室并发症并不少见。然而,关于这些患者的最佳治疗方法的数据有限。我们旨在研究肺移植后憩室炎的发生率、风险因素和结果。
我们进行了一项回顾性研究,以回顾 2007 年至 2016 年间接受肺移植且移植后发生急性结肠憩室炎的患者。根据医疗或手术管理对患者进行分组。
在 512 例移植受者中,17 例(3.32%)在中位随访 39 个月时发生 26 次憩室炎发作。9 例患者在移植前结肠镜检查中发现有憩室病。这些患者发生憩室炎手术干预的发生率更高,更有可能发生复发性憩室炎,且住院时间长于无移植前憩室病的患者。17 例患者中有 6 例(35.3%)需要手术(即,Hartmann 手术;4 例在初次发作时,2 例在第三次和第四次发作时);11 例(64.7%)单独用抗生素治疗。手术组患者在移植后更早出现症状( =.004),且接受的他克莫司剂量更高( =.03)。13 例经药物治疗的首次憩室炎发作中有 6 例(46.1%)出现复发。手术治疗后未再复发。两组均无因憩室炎导致的死亡。
与无憩室病的患者相比,移植前有憩室病的患者在移植后更早出现、更复杂的憩室炎发作。手术患者接受的他克莫司剂量更高,且比药物治疗患者更早出现症状。移植后无并发症的憩室炎患者可以用药物治疗,即使是复发性、无并发症的疾病。